We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00074737
Recruitment Status : Completed
First Posted : December 23, 2003
Last Update Posted : September 18, 2014
Information provided by (Responsible Party):
Eleos, Inc.

Brief Summary:

The principal goal of this clinical trial is to assess the ability of cenersen sodium (EL625) to improve cancer responsiveness to the established AML therapeutic agent Idarubicin used alone or in combination with Cytarabine (Ara-C).

Cenersen sodium is a drug that is designed to block the effects of a protein called p53. Laboratory evidence shows that blocking p53 will make many types of cancer, including acute myelogenous leukemia (AML), more sensitive to a variety of established cancer therapeutics while making normal tissues more resistant to the toxic effects of these agents.

Condition or disease Intervention/treatment Phase
Acute Myelogenous Leukemia Drug: cenersen Drug: Idarubicin Drug: Cytarabine Phase 2

Detailed Description:

This clinical trial is designed to assess the ability of cenersen sodium (EL625) in combination with Idarubicin alone or with Cytarabine to either: (1) induce remissions in patients who have previously failed to go into remission in response to chemotherapy; or (2) provide patents who have relapsed after going into a chemotherapy-induced remission with a longer remission.

Cenersen sodium is one of a new class of drugs called antisense oligonucleotides (oligos). Oligos are designed to block the production of specific proteins and thereby inhibit their function. Cenersen sodium targets p53, a widely studied protein.

In cancer, p53 occurs either in the un-mutated ("normal") or mutated forms. The majority of participants in this trial are expected to have un-mutated p53. Cenersen sodium is anticipated to sensitize cancers with un-mutated p53 to most established cancer therapeutics.

p53 has a pivotal role in protecting the body from cells that have suffered genetic damage and, as a result, do not function properly. The protein first senses the level of the damage and then forces the damaged cell to respond to the damage either by repairing itself or committing suicide. In general, the greater the level of damage the more likely the cellular response will be suicide.

Many cancer therapeutics, including both chemotherapy and radiation, cause the types of genetic damage that activate p53 and, consequently, cause either damage repair or cellular suicide. Laboratory studies suggest that cancer cells have a host of defenses that reduce the chances that these cells will respond to genetic damage by committing suicide. So compared to normal cells, cancer cells are more likely to repair the damage caused by cancer therapeutics while normal cells are more likely to commit suicide. Thus, blocking un-mutated p53 is more likely to prevent repair in cancer cells while preventing suicide in normal cells. This provides the basis for a differential effect of cenersen sodium on cancer cells verses normal cells.

When p53-dependent repair is prevented in cancer cells they begin to copy their damaged genetic information in preparation for cell division. This copying of the genetic damage triggers a p53-independent backup suicide mechanism and, as a result, the cancer cells are eliminated. This is the presumed mechanism whereby cenersen sodium is able to sensitize cancer cells with normal p53 function to numerous cancer therapeutics.

At higher doses however, chemotherapy sometimes blocks cells from copying their genes in preparation for division. Thus, it is possible that a chemotherapeutic agent used at a high dose could block any sensitizing effect that cenersen sodium might otherwise have on the cancer.

The chemotherapeutic agent Idarubicin is known to produce the type of genetic damage that effects p53 expression, causes p53-dependent responses and has been shown to be made more effective at killing cancer cells by cenersen sodium. Cytarabine (Ara-C) is the most widely used chemotherapeutic agent for AML. Cenersen sodium does not appear to sensitize cancer cells to Cytarabine and at higher doses Cytarabine may reduce the capacity of cenersen sodium to sensitize cancer cells.

Hence, this AML study will examine the effects of Cenersen sodium used in combination with Idarubicin and one of three different doses of Cytarabine (i.e. 0, 0.1 and 1.0 gm/m2/day), on the responsiveness of participants to these chemotherapeutic agents.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML)
Study Start Date : April 2004
Actual Primary Completion Date : May 2007
Actual Study Completion Date : May 2007

Arm Intervention/treatment
Active Comparator: cenersen, idarubicin
cenersen, idarubicin, no cytarabine
Drug: cenersen
cenersen with standard of care
Other Names:
  • cenersen sodium
  • Ol(1)p53
  • EL625
  • Aezea

Drug: Idarubicin
standard of care for AML
Other Name: idamycin

Active Comparator: cenersen, idarubicin, cytarabine
cenersen, idarubicin, standard dose cytarabine
Drug: cenersen
cenersen with standard of care
Other Names:
  • cenersen sodium
  • Ol(1)p53
  • EL625
  • Aezea

Drug: Idarubicin
standard of care for AML
Other Name: idamycin

Drug: Cytarabine
standard of care Ara-C and High dose Ara-C
Other Names:
  • Ara-C
  • HDAC

Active Comparator: cenersen, idarubicin, HDAC
cenersen, idarubicin, HDAC (high dose cytarabine)
Drug: cenersen
cenersen with standard of care
Other Names:
  • cenersen sodium
  • Ol(1)p53
  • EL625
  • Aezea

Drug: Idarubicin
standard of care for AML
Other Name: idamycin

Drug: Cytarabine
standard of care Ara-C and High dose Ara-C
Other Names:
  • Ara-C
  • HDAC

Primary Outcome Measures :
  1. Determine the effective dose of Cytarabine chemotherapy to be used in combination with EL625 and Idarubicin. [ Time Frame: 6 months ]
    Cenersen plus standard of care

Secondary Outcome Measures :
  1. Determine the safety profile for the combination of EL625 and Idarubicin +/- Cytarabine. [ Time Frame: 6 months ]
    Standard of care plus cenersen

  2. Determine the Complete Response Rate and Time to Progression. [ Time Frame: 6 months ]
    Standard of care plus cenersen

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Subjects with either refractory AML (not achieving a CR after a single course of induction), or relapsed AML that have a CR for less than one year.
  • greater or equal to 18 years old.
  • Life expectancy of more than 4 weeks following initiation of treatment.
  • Performance status (Zubrod) less or equal to 3.
  • Total Bilirubin less or equal to 1.5 x upper normal limit (UNL) unless attributable to organ infiltration by leukemia, and ALT(SGPT) less or equal to 2.5 x UNL.
  • Creatinine less or equal to 1.5 x UNL unless attributable to organ infiltration by leukemia.
  • If plasma creatinine value is borderline, creatinine clearance greater or equal to 60 ml/min (actual or calculated), serum magnesium should be within the normal value.
  • Subjects with liver and/or renal dysfunction due to organ infiltration by leukemia are eligible.
  • Left Ventricular Ejection Volume (LVEF) of >50% as determined by multi-gated acquisition scan (MUGA) or echocardiogram.
  • Able to comply with scheduled follow-up and with management of toxicity.
  • Sexually active patients must use an effective method of contraception during the study dosing period. The following are considered acceptable methods of contraception: (i) oral contraceptive pill, (ii) condom, (iii) diaphragm plus spermicide, (iv) patient or partner surgically sterile, (v) patient or partner more than 2 years post-menopausal or (vi) injectable or implantable agent/device.
  • Informed consent form obtained, signed and dated prior to initiation of treatment

Exclusion Criteria:

  • Subjects with M3 AML.
  • Subjects receiving other anti-leukemia investigational agents (i.e., unapproved drugs). However, individual cases will be considered on a case-by-case basis for other investigational agents (e.g., antibiotics, antifungals).
  • Pregnant or lactating subjects. Chemotherapy (including hydroxyurea) within three (3) weeks prior to initiation of therapy, unless there is evidence of rapidly progressive disease; then subjects may be enrolled with a minimum of two (2) weeks from previous treatments.

Prohibited Medications during the first week of each course:

  • Acetaminophen
  • Hi-Dose antioxidants (e.g., Vitamins C, E; Multivitamins)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00074737

Layout table for location information
United States, California
University of California, San Diego
La Jolla, California, United States, 92093-0960
United States, Florida
University of Miami Health Center
Miami, Florida, United States, 33136
United States, Missouri
Washington University Medical Center (Siteman Cancer Center)
St. Louis, Missouri, United States, 63110
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
North Shore University Hospital
Lake Success, New York, United States, 11041
United States, Texas
M. D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Eleos, Inc.
Layout table for investigator information
Principal Investigator: Jorge E Cortes, MD M.D. Anderson Cancer Center
Principal Investigator: Edward D. Ball, MD University of California, San Diego
Principal Investigator: John DiPersio, MD Washington University Medical Center, Siteman Cancer Center
Principal Investigator: Maria Baer Roswell Park Cancer Institute
Principal Investigator: Jonathan Kolitz, MD, FACP North Shore University Hospital
Principal Investigator: Hugo Fernandez, MD University of Miami
Additional Information:
Layout table for additonal information
Responsible Party: Eleos, Inc.
ClinicalTrials.gov Identifier: NCT00074737    
Other Study ID Numbers: ELP1001
2003-0475 (MD Anderson)
First Posted: December 23, 2003    Key Record Dates
Last Update Posted: September 18, 2014
Last Verified: September 2014
Keywords provided by Eleos, Inc.:
Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors